
The defense systems group reported 40.4% third-quarter revenue growth and kept its 2026 revenue outlook near €600 million.
Theon International reported third-quarter revenue of €134.1 million, up 40.4% from a year earlier, and an adjusted EBIT margin of 26.2%. The company reaffirmed its 2026 guidance and raised its medium-term organic revenue growth target.
For the first nine months of 2026, revenue increased 37.1% to €382.8 million, while order intake rose 22.5% to €285.2 million. Theon said it expects order intake to accelerate in the fourth quarter, supporting its full-year book-to-bill target of about 1.0.
The company maintained its 2026 revenue outlook at about €600 million and its adjusted EBIT margin guidance above 26%. It now expects capital spending of about €25 million, down from previous guidance of about €30 million, citing the timing of investments, with the balance shifting into its 2027 spending profile.
The medium-term organic revenue growth target is now above 20% per year, compared with the previous target of above 15%. Theon said its acquisition of Merio is complete, while the HGH acquisition remains in the approvals process and is on track for completion in late fourth quarter.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.